Comparison of Adagrasib and Sotoracib

Adagrasib (Adagrasib) and sotorasib (Sotorasib) are both therapeutic drugs for KRAS G12C mutated non-small cell lung cancer (NSCLC) and belong to the same category of targeted therapy drugs. However, they have some differences in some aspects, including the chemical structure of the drug, the development process, clinical trial results and potential application areas. A more detailed comparative analysis of these two drugs will be provided below.

1. Chemical structure of drug:

Adagrasib (Adagrasib): It is a small molecule targeted drug. Its mechanism of action is to inhibit the proliferation and survival of cancer cells by specifically intervening in the abnormal cell signaling caused by the KRAS G12C mutation.

Sotorasib (Sotorasib): It is also a small molecule targeted drug that acts on the KRAS G12C mutation and inhibits the growth of cancer cells by binding to the protein of the KRAS G12C mutation.

2. Research and Development History:

Adagrasib: Developed byMirati Therapeutics. The drug underwent a series of clinical trials, including early phase I/II clinical trials and later larger phase III clinical trials, to evaluate its efficacy and safety in the treatment of KRAS G12C mutated NSCLC.

Sotoracib: Developed byAmgen. Sotoraxib has also gone through multiple clinical phases, including pivotal clinical trials evaluating its efficacy and safety in the treatment of KRAS G12C mutated NSCLC.

3. Clinical trial results:

Adograceib: According to early clinical trial results, adagrasiib has shown significant efficacy in some patients with KRAS G12Cmutated NSCLC. Data from phase III clinical trials show that adagrasib has a better survival advantage than traditional chemotherapy in patients who develop resistance after treatment.

Sotoracib: Clinical trial data of sotoracib also show that the drug shows certain efficacy in some NSCLC patients carrying KRAS G12C mutations. More research is needed on its effectiveness in first-line treatment and how it compares with other treatments.

4. Potential application areas:

Adagrasib: Currently it is mainly used for patients with KRAS G12Cmutated NSCLC who have received other treatments and developed drug resistance. As research continues, it may be expanded to other cancer types in the future.

Sotoracib: It is also mainly used in patients with KRAS G12C mutationsNSCLC. Current research is mainly focused on the field of non-small cell lung cancer.

5. Side effects and safety:

Adagrasiib and sotorasiib: Both have shown some side effects in clinical trials, including but not limited to digestive system problems, skin reactions, abnormal liver function, etc. As with any medication, patients should pay close attention to possible side effects and promptly report any discomfort to their doctor.

6. Future development direction:

Adagorasib and sotorasiib: Both represent the most effective treatments forKRAS G12CInnovative directions for the treatment of mutated lung cancer. With further research and development, they may be expanded to other tumor areas in the future and may be combined with other treatments to improve patient outcomes.

Overall, adagrasiib and sotorasiib, as new therapeutic drugs targetingKRAS G12C mutations, provide a promising treatment option for patients with non-small cell lung cancer. However, patients should make decisions based on their specific circumstances and their physician's recommendations when choosing treatment. For the latest information and developments of these two drugs, patients are advised to pay attention to updates in medical literature and clinical trials.

Adagrasib is not currently available in the country, so patients cannot purchase it domestically and can only purchase adagrasib through overseas channels. Abroad, there is only the original American drug adagrasib, and the price is very high, as high as about 190,000 yuan.